AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 1, 2026
QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia February 1, 2026
Eikon Therapeutics Secures $350.7M Series D to Advance Clinical-Stage Programs and Future Pipeline February 1, 2026
Alteogen Announces Exclusive License Agreement with Tesaro for the Development of a SQ Formulation of Dostarlimab Enabled by Hybrozyme™ Technology January 26, 2026
Infinitopes Expands Seed Financing to $35M to Accelerate Clinical Development of Precision Cancer Vaccine January 26, 2026
Janux Therapeutics and Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors January 25, 2026
Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the US, China and Japan January 18, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
Bio-Sourcing, Zerion Pharma to Collaborate on First HER2 Oral Monoclonal Antibody for Breast Cancer January 18, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer January 18, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop RC148 for Advanced Solid Tumors January 18, 2026
Ferring Pharmaceuticals and Theralase Technologies to Investigate ADSTILADRIN – Ruvidar (TLD-1433) Combo in Bladder Cancer January 18, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro January 11, 2026
Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Gen Bispecific ADCs January 11, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications January 11, 2026
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies January 11, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
